Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Form 8.3 - APH LN

14 Jan 2025 15:00

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Sand Grove Capital Management LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Fund(s) for which Sand Grove Capital Management LLP serves as the Investment Manager or Discretionary Sub-Advisor

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Alliance Pharma plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

13 January 2024

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

1p ordinary

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

12,312,879

2.28%

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

12,312,879

2.28%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

1p ordinary

Purchase

1,100,000

61.15p

1p ordinary

Purchase

3,800,000

61.1p

1p ordinary

Purchase

1,200,000

61.15p

1p ordinary

Purchase

1,800,000

61.1p

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:

14 January 2024

Contact name:

James Evans

Telephone number:

+44 203 161 0743

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114766379/en/

Copyright Business Wire 2025

Date   Source Headline
1st Feb 20237:00 amRNSAppointment of NED and SID
30th Jan 20235:18 pmRNSNotification of Major Holdings
17th Jan 20237:00 amRNSFull Year Trading Update
16th Jan 20233:35 pmRNSNotification of Major Holdings
12th Jan 20237:00 amRNSSenior Management and Board Update
3rd Jan 202311:01 amRNSNotification of Major Holdings
29th Dec 202211:45 amRNSBlock Listing Six Monthly Return
22nd Dec 20229:51 amRNSNotification of Major Holdings
13th Dec 20224:58 pmRNSNotification of Major Holdings
23rd Nov 20227:00 amRNSUpdate on Q4 Trading
23rd Nov 20227:00 amRNSManagement Update
1st Nov 20225:33 pmRNSTotal Voting Rights
4th Oct 20224:48 pmRNSTotal Voting Rights
3rd Oct 20221:53 pmRNSNOTIFICATION OF MAJOR HOLDINGS
30th Sep 20224:07 pmRNSGrant of Options to Directors
20th Sep 20227:00 amRNSInterim Results
2nd Sep 20227:06 amRNSUpdate on CMA investigation
1st Sep 20225:03 pmRNSTotal Voting Rights
1st Sep 20227:00 amRNSNotification of Half Year Results
17th Aug 20221:21 pmRNSNotification of Major Holdings
17th Aug 20227:00 amRNSNotification of Major Holdings
8th Aug 20227:00 amRNSChange of Auditor
1st Aug 20226:02 pmRNSTotal Voting Rights
20th Jul 20227:00 amRNSHalf Year Trading Update
1st Jul 202210:14 amRNSTotal Voting Rights
30th Jun 202210:14 amRNSBlock Listing Six Monthly Return
17th Jun 20224:00 pmRNSBlock Admission Application
8th Jun 20227:00 amRNSTotal Voting Rights
26th May 20227:00 amRNSNotification of Major Holdings
18th May 20223:42 pmRNSResult of AGM
18th May 20227:00 amRNSDirectorate Changes
18th May 20227:00 amRNSAGM Statement
3rd May 20221:18 pmRNSTotal Voting Rights
12th Apr 202211:30 amRNSPosting of Annual Report and Notice of AGM
6th Apr 202211:12 amRNSNotification of Major Holdings
5th Apr 202210:02 amRNSAnnual Report and Notice of AGM
4th Apr 202211:17 amRNSTotal Voting Rights
25th Mar 202210:48 amRNSAcquisition to access US scar treatment market
22nd Mar 20227:00 amRNSResults for the year ended 31 December 2021
21st Mar 20221:30 pmRNSStatement regarding potential acquisition
15th Mar 20224:15 pmRNSNotification of Major Holdings
1st Mar 20223:32 pmRNSTotal Voting Rights
15th Feb 20227:00 amRNSNotification of Full Year Results
3rd Feb 20222:42 pmRNSNotification of Major Holdings
3rd Feb 20227:09 amRNSUpdate on CMA investigation
1st Feb 20224:32 pmRNSTotal Voting Rights
18th Jan 20227:30 amRNSNotification of Major Holdings
18th Jan 20227:00 amRNSFull Year Trading Update
4th Jan 20226:04 pmRNSTotal Voting Rights
29th Dec 20219:27 amRNSBlock Listing Six Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.